<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538862</url>
  </required_header>
  <id_info>
    <org_study_id>VICCNCPED1210</org_study_id>
    <nct_id>NCT01538862</nct_id>
  </id_info>
  <brief_title>Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa</brief_title>
  <official_title>Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is
      effective as a treatment of Dystrophic Epidermolysis Bullosa (EB.) Patients will receive one
      course of treatment with the study drug. The course will be 7 days in length. After
      receiving GCSF, patients will be followed at 7 and 30 days following the discontinuation of
      the drug. Thirty day follow up can be done via telephone communication with the patient or
      family.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of active blisters</measure>
    <time_frame>30 days</time_frame>
    <description>Reduction in active blisters and in total blister/erosion counts by at least 30%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surface area of nonhealing erosions</measure>
    <time_frame>30 days</time_frame>
    <description>Reduction in surface area of one or two nonhealing erosions by at least 20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall symptomatology</measure>
    <time_frame>30 days</time_frame>
    <description>Overall clinical improvement in symptomatology and/or findings, as assessed by either the patient or parent, of at least 30%</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>GCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor (GCSF)</intervention_name>
    <description>G-CSF 10mcg/kg/d SQ for 7 days</description>
    <arm_group_label>GCSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Each patient must have the diagnosis of severe generalized recessive dystrophic EB
             (formerly known as Hallopeau-Siemens RDEB) confirmed by clinical criteria and either
             of the following:

               1. transmission electron microscopy

               2. immunofluorescence antigenic mapping and type VII collagen monoclonal antibody
                  staining

               3. COL7A1 mutational analysis

        Exclusion Criteria:

          -  The patient must not have a history of squamous cell carcinoma or any internal
             malignancy.

          -  Female patients who are pregnant.

          -  Patients with active signs and symptoms of infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haydar Frangoul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 5, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Haydar Frangoul</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
